Success Metrics

Clinical Success Rate
81.7%

Based on 348 completed trials

Completion Rate
82%(348/426)
Active Trials
67(10%)
Results Posted
49%(169 trials)
Terminated
78(12%)

Phase Distribution

Ph early_phase_1
27
4%
Ph phase_1
79
12%
Ph phase_2
240
36%
Ph not_applicable
82
12%
Ph phase_4
110
16%
Ph phase_3
128
19%

Phase Distribution

106

Early Stage

240

Mid Stage

238

Late Stage

Phase Distribution666 total trials
Early Phase 1First-in-human
27(4.1%)
Phase 1Safety & dosage
79(11.9%)
Phase 2Efficacy & side effects
240(36.0%)
Phase 3Large-scale testing
128(19.2%)
Phase 4Post-market surveillance
110(16.5%)
N/ANon-phased studies
82(12.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.7%

348 of 472 finished

Non-Completion Rate

26.3%

124 ended early

Currently Active

67

trials recruiting

Total Trials

667

all time

Status Distribution
Active(77)
Completed(348)
Terminated(124)
Other(118)

Detailed Status

Completed348
unknown114
Terminated78
Withdrawn46
Recruiting45
Active, not recruiting22

Development Timeline

Analytics

Development Status

Total Trials
667
Active
67
Success Rate
81.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 127 (4.1%)
Phase 179 (11.9%)
Phase 2240 (36.0%)
Phase 3128 (19.2%)
Phase 4110 (16.5%)
N/A82 (12.3%)

Trials by Status

completed34852%
active_not_recruiting223%
recruiting457%
terminated7812%
not_yet_recruiting101%
withdrawn467%
unknown11417%
suspended41%

Recent Activity

Clinical Trials (667)

Showing 20 of 667 trialsScroll for more
NCT06347770Phase 1

The Effect of Oral Gan Shuangbi During the Perinatal Period on the Recovery of Intestinal Function After Cesarean Section in Pregnant Women- A Multicenter, Double-blind, Randomized Controlled Clinical Trial

Recruiting
NCT06617832Not Applicable

Trial Designs for Evaluating Migraine Treatment

Recruiting
NCT03113994Phase 2

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

Terminated
NCT03250338Phase 3

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Completed
NCT03672487Phase 3

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Completed
NCT03535272Phase 3

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

Terminated
NCT06563895Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Recruiting
NCT04734080Phase 4

Dronabinol in Total Knee Arthroplasty (TKA)

Completed
NCT04140721Early Phase 1

Autonomic Determinants of POTS - Pilot 2

Active Not Recruiting
NCT04394416Phase 3

Trial of Imatinib for Hospitalized Adults With COVID-19

Terminated
NCT03617679Phase 2

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Completed
NCT04107727Phase 2

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Completed
NCT07052799Phase 3

Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy

Recruiting
NCT03468556Phase 2

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

Not Yet Recruiting
NCT07118618Phase 2

Probenecid Administration for Alcohol Craving and Consumption

Recruiting
NCT04153136Phase 2

The ENCHANTMENT HIV Study

Completed
NCT07018622Phase 2

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Recruiting
NCT03586284Phase 2

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

Terminated
NCT04224493Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Recruiting
NCT07429565Phase 1

Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
667